- Home
- GXAI vs INBS Comparison
GXAI vs INBS Comparison
Compare GXAI & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- INBS
- Stock Information
- Founded
- GXAI 2021
- INBS 2016
- Country
- GXAI United States
- INBS United States
- Employees
- GXAI N/A
- INBS N/A
- Industry
- GXAI
- INBS Medical Specialities
- Sector
- GXAI
- INBS Health Care
- Exchange
- GXAI Nasdaq
- INBS Nasdaq
- Market Cap
- GXAI 7.6M
- INBS 8.6M
- IPO Year
- GXAI 2023
- INBS N/A
- Fundamental
- Price
- GXAI $1.14
- INBS $1.30
- Analyst Decision
- GXAI
- INBS
- Analyst Count
- GXAI 0
- INBS 0
- Target Price
- GXAI N/A
- INBS N/A
- AVG Volume (30 Days)
- GXAI 165.5K
- INBS 86.4K
- Earning Date
- GXAI 05-13-2025
- INBS 05-07-2025
- Dividend Yield
- GXAI N/A
- INBS N/A
- EPS Growth
- GXAI N/A
- INBS N/A
- EPS
- GXAI N/A
- INBS N/A
- Revenue
- GXAI $4,027.00
- INBS $3,031,405.00
- Revenue This Year
- GXAI N/A
- INBS $280.88
- Revenue Next Year
- GXAI N/A
- INBS $126.26
- P/E Ratio
- GXAI N/A
- INBS N/A
- Revenue Growth
- GXAI 1473.05
- INBS 23.21
- 52 Week Low
- GXAI $1.00
- INBS $1.00
- 52 Week High
- GXAI $7.50
- INBS $3.04
- Technical
- Relative Strength Index (RSI)
- GXAI 47.93
- INBS 39.13
- Support Level
- GXAI $1.00
- INBS $1.34
- Resistance Level
- GXAI $1.18
- INBS $1.35
- Average True Range (ATR)
- GXAI 0.10
- INBS 0.12
- MACD
- GXAI 0.00
- INBS 0.02
- Stochastic Oscillator
- GXAI 51.85
- INBS 57.14
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).